Prognostic biomarker shows promise for CVD therapy, suggesting future clinical relevance in cardiovascular disease.
SN is a prognostic biomarker in CVD, and unraveling the underlying pathophysiology of SN will be important to advance SN as a biomarker and potential future therapy in CVD. The future for SN as a biomarker and therapy is attractive and could be of future clinical relevance.
No takes yet. Share an insight, caveat, or question.
Ottesen et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Expert Review of Cardiovascular Therapy